Williams R, Karuranga S, Malanda B, et al. Global and regional estimates and projections of diabetes-related health expenditure: results from the International Diabetes Federation Diabetes Atlas[J]. Diabetes Research and Clinical Practice, 2020: 108072.
 Rajesh P, Manish K, Deepmala V, et al. Antidiabetic effect of Morinda citrofolia and Coccinia indica in alloxan induced diabetic rats[J]. Advances in Bio Research, 2010, 1(1): 75-77.
 Brocker C, Thompson D C, Vasiliou V. The role of hyperosmotic stress in inflammation and disease[J]. Biomolecular concepts, 2012, 3(4): 345-364.
 Nasteska D, Hodson D J. GPR119 Agonism Revisited: A Novel Target for Increasing β-Cell Mass?[J]. Endocrinology, 2020, 161(2): bqz018.
 Overton H A, Fyfe M C T, Reynet C. GPR119, a novel G protein‐coupled receptor target for the treatment of type 2 diabetes and obesity[J]. British journal of pharmacology, 2008, 153(S1): S76-S81.
 Little T J, Isaacs N J, Young R L, et al. Characterization of duodenal expression and localization of fatty acid-sensing receptors in humans: relationships with body mass index[J]. American Journal of Physiology-Gastrointestinal and Liver Physiology, 2014, 307(10): G958-G967.
 Soga T, Ohishi T, Matsui T, et al. Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor[J]. Biochemical and biophysical research communications, 2005, 326(4): 744-751.
 Dhayal S, Morgan N G. The significance of GPR119 agonists as a future treatment for type 2 diabetes[J]. Drug News Perspect, 2010, 23(7): 418-424.
 Matsumoto K, Yoshitomi T, Ishimoto Y, et al. DS-8500a, an orally available G protein-coupled receptor 119 agonist, upregulates glucagon-like peptide-1 and enhances glucose-dependent insulin secretion and improves glucose homeostasis in type 2 diabetic rats[J]. Journal of Pharmacology and Experimental Therapeutics, 2018, 367(3): 509-517.
 Cornall L M, Mathai M L, Hryciw D H, et al. Is GPR119 agonism an appropriate treatment modality for the safe amelioration of metabolic diseases?[J]. Expert opinion on investigational drugs, 2013, 22(4): 487-498.